KCNN4 and neoplasm: Additionally, several studies, which report findings that contrast with those of the present study, have demonstrated that KCa3.1 inhibitors can attenuate tumor progression and improve clinical outcomes by modulating the phenotypic and functional properties of immune cells within the TME.